Molecular Formula | C11H13NO4 |
Molar Mass | 223.23 |
Solubility | DMSO: < 5.8 mg/mL |
Storage Condition | Store at RT |
In vitro study | E4CPG acts at rat cortical mGluR with the K B value of 0.367 mM. |
In vivo study | E4CPG (3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.), and 1-10 nmol/site (i.c.v.)) significantly inhibits the nociception induced by the Glutamate-injection (i.pl.; 30 μmol/paw), and the maximal inhibition values for the antinociceptive action of E4CPG in Glutamate-induced nociception are 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.) . E4CPG (35 nM/3.5 μL, i.c.v.) completely blocks long-term depression (LTD) induced by the group I mGluR agonist Dihydroxyphenylglycine (DHPG, 100 nM/5 μL, i.c.v.) in male Sprague-Dawley rats. Animal Model: Male Swiss mice (25-35 g) Dosage: 3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.) and 1-10 nmol/ site (i.c.v.) Administration: Single injection Result: The maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced nociception were 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.). Animal Model: Male Sprague-Dawley rats Dosage: 35 nM/3.5 μL Administration: Single injection, i.c.v. Result: Completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.48 ml | 22.399 ml | 44.798 ml |
5 mM | 0.896 ml | 4.48 ml | 8.96 ml |
10 mM | 0.448 ml | 2.24 ml | 4.48 ml |
5 mM | 0.09 ml | 0.448 ml | 0.896 ml |
Biological activity | E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (Group I/Group II metabotropic glutamate receptor) antagonist. E4CPG can suppress the pairwise pulse ratio of postsynaptic current (IPSC) enhancement in mono-postsynaptic mechanisms. |
target | mGluR |
in vitro study | E4CPG acts at rat cortical mGluR with the K B value of 0.367 mM. |
in vivo study | E4CPG (3-30 nmol/site (I. t.), 1-10 μmol/paw (I. pl.), and 1-10 nmol/site (I. c.v.)) significantly inhibits the nociception induced by the Glutamate-injection (I. pl.; 30 μmol/paw), and the maximal inhibition values for the antinociceptive action of E4CPG in Glutamate-induced nociception are 48% (I. pl.), 49% (I. t.) and 40% (I. c.v.) . E4CPG (35 nM/3.5 μ L, I. c.v.) completely blocks long-term depression (LTD) induced by the group I mGluR agonist Dihydroxyphenylglycine (DHPG, 100 nm/5 μ l, I. c.v.) in male Sprague-Dawley rats. Animal model: male Swiss mice (25-35g) dosage: 3-30 nmol/site (I. t.), 1-10 μ mol/paw (I. pl.) and 1-10 nmol/site (I. c.v.) Administration: Single injection Result: the maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced nociception were 48% (I. pl.), 49% (I. t.) and 40% (I. c.v.). Animal Model: Male Sprague-Dawley rats Dosage: 35 nM/3.5 μL Administration: Single injection, I. c.v. Result: completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG). |
Animal Model: | Male Swiss mice (25-35 g) Male Sprague-Dawley rats |
Dosage: | 3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.) and 1-10 nmol/ site (i.c.v.) 35 nM/3.5 μL |
Administration: | Single injection Single injection, i.c.v. |
Result: | The maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced
nociception were 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.). Completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG). |